Gary Karlin, MD
Urology · Lawrenceville, NJNPI 1457334575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,330 and has fallen 92.0% since, to $106 in 2025.
Across 222 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$578
- Astellas Pharma US Inc$352
- Dendreon Pharmaceuticals LLC$331
- AbbVie$326
- Procept Biorobotics Corporation$279
- Teleflex LLC$156
- plus $1K from 30 others
Across 4 payments — averaging $5625.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$15K
- Janssen Research & Development, LLC$7K
- Eli Lilly$73
What the payments were for
- Food & beverage$3,35896%
- Education$1504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $578 |
| Astellas Pharma US Inc | 30 | $352 |
| Dendreon Pharmaceuticals LLC | 19 | $331 |
| AbbVie(2 entities) | 28 | $326 |
| Procept Biorobotics Corporation | 4 | $279 |
| Teleflex LLC | 5 | $156 |
| Pfizer | 11 | $151 |
| Bayer | 6 | $122 |
| Axonics, Inc. | 9 | $122 |
| Boston Scientific | 6 | $118 |
| Myriad Genetic Laboratories, Inc. | 7 | $102 |
| Myovant Sciences Inc. | 6 | $82 |
| Olympus America Inc. | 5 | $78 |
| Amgen | 5 | $73 |
| Endo Pharmaceuticals Inc. | 5 | $70 |
| AstraZeneca | 5 | $68 |
| Antares Pharma, Inc. | 4 | $58 |
| Coloplast | 4 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Urovant Sciences Inc | 3 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $34 |
| Calyxo, Inc. | 1 | $30 |
| Merck | 2 | $30 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Verity Pharmaceuticals Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Neotract Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Novartis | 1 | $18 |
| KARL Storz Endoscopy-america | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $14 |
| Palette Life Sciences, Inc. | 1 | $13 |
| Metuchen Pharmaceuticals | 1 | $13 |
| 180 Medical, Inc. | 1 | $12 |
| Photocure Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,508 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 68 | $947,219 |
| MyrbetriqMirabegron | 239 | $210,447 |
| GemtesaVibegron | 132 | $135,298 |
| Abiraterone Acetate | 41 | $68,956 |
| Tamsulosin Hcl | 738 | $12,507 |
| Desmopressin Acetate | 90 | $12,321 |
| Silodosin | 109 | $10,905 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 57 | $8,123 |
| Potassium Citrate ErPotassium Citrate | 52 | $6,284 |
| Solifenacin Succinate | 85 | $6,019 |
| Testosterone | 62 | $5,478 |
| Finasteride | 334 | $5,087 |
| Methenamine Hippurate | 34 | $4,591 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $3,989 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 15 | $3,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $352 | $1,157,666307 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $135,298132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.
Other urology in Lawrenceville
- Ravi RajanLawrenceville$79K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.